Compare Ginkgo Bioworks Holdings Inc (DNA) vs Marqeta Inc (MQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ginkgo Bioworks Holdings Inc vs Marqeta Inc — how do they compare? Ginkgo Bioworks Holdings Inc trades at $7.33 (market cap $505.73M), while Marqeta Inc trades at $15.46 (market cap $1.62B). The key difference: Marqeta Inc is far larger — about 3.2× Ginkgo Bioworks Holdings Inc's market cap, and Ginkgo Bioworks Holdings Inc is trading nearer its 52-week high, Marqeta Inc nearer its low. Which is the better fit depends on your goals.
| DNA | MQ | |
|---|---|---|
Market Cap | $505.73M | $1.62B |
Sector | Health | Technology |
52-Week High | $16.14 | $26.00 |
52-Week Low | $5.48 | $15.04 |
Enterprise Value | $607.68M | $935.36M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ginkgo Bioworks (DNA) trades at $7.29, down 4.71% with bearish technical signals. The company reported Q2 2026 revenue of $20 million, down 48% year-over-year, continuing its strategic pivot to autonomous labs. Despite beating EPS expectations in two of the last three quarters, DNA shows negative profitability with -219.6% net income margin and negative cash flow. Analyst sentiment is mixed with 45% buy ratings but significant institutional selling pressure.
DNA faces substantial execution risk during its business transition, with declining revenue and persistent losses offset by potential in autonomous laboratory technology. The stock's current valuation at 3.61x sales appears stretched given negative earnings, requiring successful operational turnaround for sustainable recovery. Near-term catalysts depend on revenue stabilization and cost management improvements.
Marqeta (MQ) trades at $15.6, down 2.26% on the day, with a bearish technical outlook and mixed fundamentals. The stock recently underwent a 4:1 reverse split and shows improving revenue trends, though profitability remains thin. Recent news highlights partnerships with Google and Riskified to expand product offerings and reduce fraud.
The outlook is cautiously optimistic due to revenue growth and strategic expansions, but high valuation ratios and inconsistent earnings pose risks. Analyst consensus is a Buy with a $19 price target, suggesting potential upside if execution improves and margins expand.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ginkgo Bioworks Holdings Inc
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →About Marqeta Inc
Headquartered in Oakland, California, and founded in 2010, Marqeta provides its clients with a card-issuing platform that offers the infrastructure and tools necessary to offer digital, physical, and tokenized payment options without the need for a traditional bank. The company's open APIs are designed to allow third parties like DoorDash, Klarna, and Block to rapidly develop and deploy innovative card-based products and payment services without the need to develop the underlying technology. The company generates revenue primarily through processing and ATM fees for cards issued on its platform.
Read more on MQ →
